Fill finish CDMO selection and the biologics supply chain

Selecting a partner

1. Name the capability, not the category. Bulk manufacture, sterile filling, potent handling and chemical synthesis are different plants. A partner excellent at one may subcontract another, which changes accountability and lead time.
2. Treat sterile filling as the scarce step. Filling capacity with the right container formats and the right containment is frequently harder to book than bulk capacity, and it sits at the end of the timeline where delay is most expensive.
3. Assess the quality system, not the equipment list. Deviation handling, change control, data integrity and the last inspection outcome predict batch success better than any equipment inventory. Ask to see the systems, not the suite.
4. Establish who owns the process. A platform partner runs their process and gives speed at the cost of portability. A contract manufacturer runs yours. Both are valid and the difference decides whether you can ever move.
5. Confirm containment for potent payloads. Highly potent material requires containment engineering, occupational exposure monitoring and cleaning verification between products. Not every biologics site can take that work, and it narrows the list early.
6. Negotiate failure and reslot before signing. What happens when a batch fails release, who pays, how quickly a slot reopens and what data you receive. These terms are far easier to agree before a campaign than during one.

The scarce step sets the timeline

Programmes plan around bulk manufacture and are delayed by filling, analytics or release testing. Identifying the scarce step for your specific product and booking it first is the most effective schedule protection available.

Ask each candidate which step is their constraint. The honest ones will tell you, and the answer is more useful than a capacity brochure.

Quality systems predict outcomes

How a site handles a deviation, controls a change and manages its records predicts whether your batch will be released. Equipment lists predict very little, because everyone has similar equipment.

Audit the systems, read the inspection history, and speak to a reference customer at a similar scale.

cdmo biotech, and what a biotech buyer needs from one

A biotech without a plant buys capability and calendar. The capability questions are the platform, the scale, the analytical development and the regulatory support; the calendar question is the slot, and it is often the binding constraint. What a small company also needs, and rarely negotiates hard enough, is the technology transfer package, ownership of process knowledge and analytical methods, the right to audit, and terms for a failed batch. Ask who writes the chemistry and manufacturing sections of a filing, since that work sits on the critical path to the clinic.

An ipsc cdmo, and what to ask before a slot

A cell therapy programme on induced pluripotent stem cells needs a provider whose platform matches the product: a reprogramming and banking route with documented provenance and consent for the donor line, differentiation under defined conditions, and a release panel covering identity, potency, residual undifferentiated cells and genomic stability. Ask which parts are run in the building you will be audited in, what scale a batch is in cells rather than litres, and how the cryopreservation and shipping validation was done.

A microbial cdmo, and what differs from a mammalian one

Microbial manufacture is fast, dense and hot: fermentation in hours rather than weeks, high cell densities, a heavy heat and oxygen load, and a product that is often inside the cell, which puts lysis and refolding into the process. Endotoxin clearance and host cell protein profiles are the analytical burden. A mammalian CDMO's suites, skills and analytics do not transfer, so the platform question comes first: ask what the plant has run at your scale, and whether inclusion body refolding is in their experience.

Bioprocessing companies and how the market divides

Bioprocessing companies fall into equipment and consumable suppliers, contract developers and manufacturers, and the specialist service firms around them, and a buyer usually needs two of the three. The question that separates them commercially is who holds the process knowledge afterwards. Capacity, the regulatory track record of the site and the technology transfer terms are what a selection actually compares.

cdmo drug development and where the handover sits

In cdmo drug development the boundary between the sponsor's process and the contractor's platform is the term that matters most later: a platform process is faster to a first batch and harder to move. Stage gates, the analytical package and who owns the cell line and the methods belong in the contract. Timeline slippage is usually analytical method transfer rather than manufacturing.

A plasmid cdmo and the grade the plasmid is for

A plasmid cdmo is selected by the grade its plasmid supports, research, high quality for preclinical, or full good manufacturing practice for a starting material, and the price between those differs by more than an order of magnitude. Supercoiled percentage, residual host DNA, RNA, protein and endotoxin are the specification. Lead time is driven by the release testing rather than by the fermentation.

aav analysis and the assays a release panel needs

aav analysis is a panel rather than a test: titre by genome copies and by capsid, the ratio between them, empty to full capsid content, residual host cell DNA and plasmid, aggregation and potency. Each has a method choice with its own bias, which is why an assay list without the methods cannot be compared between suppliers. Reference material availability limits every comparison.

Common questions

Why is sterile fill-finish harder to book than bulk?

Because sterile filling suites are fewer, are shared across many products, and require format specific change over and validation. It is the step where timelines most often slip.

What separates a good partner from a cheap one?

The quality system and slot reliability. A failed batch or a missed slot costs far more than the difference in price, and both are predicted by deviation handling and inspection history rather than by equipment.

Can a process be moved between partners?

Only if you own it and it was documented to transfer. Platform processes generally are not portable, which is a reasonable trade to make knowingly and a painful one to discover.

Browse by service class

• Compare Gene synthesis on advertised prices